The following list has been reviewed and approved by the European Society of Urogenital Radiology’s (ESUR)’s Women’s Pelvic Imaging Group.
|
OVARY |
Technique |
Level of |
Single centre/ |
Indication |
Patient prep |
Data acquisition |
Image processing |
|
Recommended |
RECIST 1.1 combined with CA 125
|
511! |
Consensus |
Response to systemic treatment |
No |
CE-CT |
Manual documentation by trained observer |
|
Recommended biomarkers/ |
Morphology (solid-cystic mass, papillary projections, etc.) |
12-3! |
Multicentre-IOTA |
Differentiate benign from malignant |
IM antiperistaltic agent |
High resolution T2, standard T1 and T1 FS, T1 FS with gadolinium |
Manual documentation by trained observer |
|
Dynamic contrast uptake pattern |
34-7! |
Single centre |
Differentiate benign from malignant |
IM anitperistaltic agent |
Temporal resolution < 15 sec |
Construction of time-intensity-curves comparing |
|
|
DWI (visual) |
38! |
Single centre |
Diagnosis and staging |
1L pineapple juice |
At least 2 b-values (b=0-50 and b=800-1000 s/mm2) |
Manual documentation by trained observer |
|
|
Multiparametric model |
19-10! |
Single centre |
Differentiate benign from malignant |
IM antiperistaltic agent |
Conventional MRI + DWI + DCE |
Visual interpretation of mass characteristics and TICs |
|
|
Biomarkers in development/ |
ADC |
112-13! |
Single centre |
Differentiate benign from malignant, histopathological tumour features |
IM antiperistaltic agent |
At least 2 b-values (b=0-50 and b=800-1000 s/mm2) |
Considerable overlap8 |
|
ADC histogram analysis |
114! |
Single centre |
Response to systemic treatment |
IM antiperistaltic agent |
At least 2 b-values (b=0-50 and b=800-1000 s/mm2) |
First order histogram parameters |
|
|
Multiparametric MRI (ADC, ve, MRS) |
115! |
Single centre |
Response to systemic treatment |
IM anitperistaltic agent |
Multiple b-values |
Monoexponential data fit, Tofts model |
|
|
Radiomics (CT) |
316! |
Single centre |
Outcome prediction |
No |
CE-CT |
No consensus available |
- Schweitzer ME. Evidence level. J Magn Reson Imaging. 2016;43(3):543-543. doi:10.1002/jmri.25187
- Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group. Ultrasound Obstet Gynecol. 2000;16(5):500-505. doi:10.1046/j.1469-0705.2000.00287.x
- Meys EMJ, Kaijser J, Kruitwagen RFPM, et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. Eur J Cancer. 2016;58:17-29. doi:10.1016/j.ejca.2016.01.007
- Bernardin L, Dilks P, Liyanage S, Miquel ME, Sahdev A, Rockall A. Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlation. Eur Radiol. 2012;22(4):880-890. doi:10.1007/s00330-011-2331-z
- Thomassin-Naggara I, Bazot M, Daraï E, Callard P, Thomassin J, Cuenod CA. Epithelial Ovarian Tumors: Value of Dynamic Contrast-enhanced MR Imaging and Correlation with Tumor Angiogenesis. Radiology. 2008;248(1):148-159. doi:10.1148/radiol.2481071120
- Thomassin-Naggara I, Balvay D, Aubert E, Daraï E, Rouzier R, Cuenod CA, Bazot M. Quantitative dynamic contrast-enhanced MR imaging analysis of complex adnexal masses: a preliminary study. Eur Radiol. 2012 Apr;22(4):738-45. doi: 10.1007/s00330-011-2329-6. Epub 2011 Nov 23. PubMed PMID: 22105841.
- Thomassin-Naggara I, Soualhi N, Balvay D, Darai E, Cuenod CA. Quantifying tumor vascular heterogeneity with DCE-MRI in complex adnexal masses: A preliminary study. J Magn Reson Imaging. 2017 Dec;46(6):1776-1785. doi: 10.1002/jmri.25707. Epub 2017 Apr 3. PubMed PMID: 28370815.
- Thomassin-Naggara I, Toussaint I, Perrot N, et al. Characterization of Complex Adnexal Masses: Value of Adding Perfusion- and Diffusion-weighted MR Imaging to Conventional MR Imaging. Radiology. 2011;258(3):793-803. doi:10.1148/radiol.10100751
- Thomassin-Naggara I, Aubert E, Rockall A, et al. Adnexal Masses: Development and Preliminary Validation of an MR Imaging Scoring System. Radiology. 2013;267(2):432-443. doi:10.1148/radiol.13121161
- Thomassin-Naggara I, Poncelet E, Jalaguier-Coudray A, Guerra A, Fournier LS, Stojanovic S, Millet I, Bharwani N, Juhan V, Cunha TM, Masselli G, Balleyguier C, Malhaire C, Perrot NF, Sadowski EA, Bazot M, Taourel P, Porcher R, Darai E, Reinhold C, Rockall AG. Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging (O-RADS MRI) Score for Risk Stratification of Sonographically
Indeterminate Adnexal Masses. JAMA Netw Open. 2020 Jan 3;3(1):e1919896. doi: 10.1001/jamanetworkopen.2019.19896. PubMed PMID: 31977064; PubMed Central PMCID: PMC6991280. - Rustin GJS, Vergote I, Eisenhauer E, et al. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419-423. doi:10.1097/IGC.0b013e3182070f17
- Kim H-J, Lee S-Y, Shin YR, Park CS, Kim K. The Value of Diffusion-Weighted Imaging in the Differential Diagnosis of Ovarian Lesions: A Meta-Analysis. Cao C, ed. PLoS One. 2016;11(2):e0149465. doi:10.1371/journal.pone.0149465
- Lindgren A, Anttila M, Rautiainen S, et al. Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRI. Eur Radiol. 2017;27(9):4002-4012. doi:10.1007/s00330-017-4786-z
- Kyriazi S, Collins DJ, Messiou C, et al. Metastatic Ovarian and Primary Peritoneal Cancer: Assessing Chemotherapy Response with Diffusion-weighted MR Imaging—Value of Histogram Analysis of Apparent Diffusion Coefficients. Radiology. 2011;261(1):182-192. doi:10.1148/radiol.11110577
- Sala E, Kataoka MY, Priest AN, et al. Advanced Ovarian Cancer: Multiparametric MR Imaging Demonstrates Response- and Metastasis-specific Effects. Radiology. 2012;263(1):149-159. doi:10.1148/radiol.11110175
- Rizzo S, Botta F, Raimondi S, et al. Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months. Eur Radiol. May 2018. doi:10.1007/s00330-018-5389-z